Category Stock News

AU Small Finance Bank Ltd
Why AU Small Finance Bank is a Strong Bet Despite Stock Correction in 2025

Business and Industry Overview: 

AU Small Finance Bank is India’s largest small finance bank. It is based in Jaipur. It started in 1996 as a company that gave loans for buying vehicles. In 2017, it became a full bank. The bank helps people with low and middle incomes. It also helps small businesses. It gives loans, savings accounts, and other banking services. People can use UPI, mobile banking, and other digital services. The bank is listed on the stock market. Big investors like Warburg Pincus and International Finance Corporation have invested in it. In 2024, AU Bank merged with Fincare Small Finance Bank. This was the first merger between small banks. The bank has 2,383 branches in 25 states. It has 46,000 employees and 1.1 crore customers. It also has 505 ATMs across India. Its total deposits are ₹80,120 crore, and its total loans are ₹67,624 crore. The bank is growing fast. It is using technology to make banking easy. In 2023, it started a campaign with Bollywood actress Kiara Advani. The bank is strong and trusted. 

Small Finance Banks (SFBs) are special banks in India that help small businesses, low-income people, and rural areas get banking services. They provide loans, savings accounts, deposits, and online banking. The industry is growing fast, with banks like AU Small Finance Bank and Ujjivan Small Finance Bank leading the way. SFBs are expanding quickly in rural and small-town areas, where many people do not have access to banks. In 2024, these banks are expected to grow their loans by 25–27%.  mainly give loans for small businesses, homes, vehicles, and personal use. However, they face challenges in getting deposits because they offer higher interest rates to attract customers. To solve this, they are using other ways to get money, like selling loan portfolios to investors. Many SFBs have strong financial backing and are raising funds from investors and stock markets. They have also increased their capital reserves to remain stable. In the future, these banks will continue growing, especially in small towns and villages, helping more people and businesses get access to banking. 

AU Small Finance Bank is the biggest small finance bank in India. It started as a finance company in 1996. In 2017, it became a small finance bank. It helps people and small businesses who cannot use big banks. The bank has grown very fast. It is now listed on the stock market. AU Bank has 2,383 branches across 25 states. It serves over 1.1 crore customers. Many of them live in villages and small towns. These places need better banking services. AU Bank gives loans, savings accounts, and other banking services. The bank uses technology to help customers. People can use online banking, video banking, and mobile banking. This makes banking easy and fast. The bank is strong financially. It has total assets of ₹1,01,176 crore. It has a good reputation and high credit ratings. AU Bank became more popular after a marketing campaign with Bollywood actress Kiara Advani. In 2024, it merged with Fincare Small Finance Bank. This made it even bigger. 

The bank faces competition. Other small finance banks and big banks like HDFC and ICICI are its rivals. AU Bank offers higher interest rates to attract customers. It also reaches more villages and small towns. Its focus on technology and customer service makes it one of the best small finance banks in India. 

Latest Stock News: 

AU Small Finance Bank’s stock was moving between ₹540 and ₹730 for two years. Now, it has fallen below ₹540. If it stays below this level, the price may drop by 25-30%. The RSI, which shows stock strength, is moving toward the oversold zone. This means selling pressure is high, and the stock may fall more. 

On March 17, the stock fell 2.7% and hit ₹478.35, its lowest price in a year. Since the start of 2025, it has dropped by 13%. This happened even when the overall stock market was doing well. NIFTY 50 rose by 0.50%, and SENSEX went up by 0.46%. The bank plans to raise ₹1,500 crore by selling special bonds. This will help strengthen its financial position. The bank’s total fundraising limit is ₹6,000 crore, approved in July 2024. Many other stocks also fell. A total of 199 stocks, including RR Kabel, Rolex Rings, and Muthoot Microfin, hit their lowest prices in a year. Despite this, the overall market remained strong. NIFTY 50 was up by 1.2%, and SENSEX increased by 1.31%. The bank is working to improve its finances, but investors are still unsure. The next few weeks will decide if the stock will recover or fall further. 

Segmental information: 

  1. Retail Banking: This includes savings accounts, current accounts, fixed and recurring deposits, debit and credit cards, and personal loans like home, car, and two-wheeler loans.
  1. Business Banking: This helps small and medium businesses. The bank offers loans for working capital, MSME financing, and current accounts for businesses.
  1. Loan Products: The bank gives loans like personal loans, home loans, car loans, commercial vehicle loans, and gold loans.
  1. Digital Banking: The AU 0101 app and NetBanking let customers use banking services online. This includes managing FASTag, making deposits, and other services. 
  1. Insurance and Investments: The bank offers insurance for life, health, motor, and general needs. It also provides investment products like mutual funds, NPS (National Pension System), and Atal Pension Yojana.
  1. Asset Management: The bank helps customers manage and grow their investments in different financial assets. 

Subsidiary information: 

  1. AU Housing Finance Limited (AuHFL): This subsidiary gives home loans to customers. It helps people buy homes and offers other housing finance products.
  1. AU Insurance Broking Services Private Limited: This subsidiary helps customers find and manage different types of insurance.
  1. Fincare Small Finance Bank: In April 2024, AU Small Finance Bank merged with Fincare Small Finance Bank. This merger helped AU expand, especially in South India. Fincare’s shareholders got AU Small Finance Bank shares in exchange. 
     

Q4 Highlights: 

  • Net Profit: The bank made ₹2,106 crore in profit for FY25, which is 37% more than last year (₹1,534.72 crore). For Q4, the profit was ₹503.7 crore, up 36% from ₹370.74 crore in the same quarter last year.
  • Total Income: In Q4, the bank earned ₹5,031.27 crore, which is more than last year’s ₹3,370.51 crore. 
  • Interest Income: The bank earned ₹4,270.60 crore from interest, a 51% increase compared to last year.
  • Dividend: The bank’s board has recommended a dividend of ₹1 per share (10% of face value). This will be approved at the next Annual General Meeting. 
     

Financial Summary: 

Amount in ₹ Crore Q4 FY24 Q4 FY25 FY23 FY24 
Revenue 2,830 4,271 10,555 16,064 
Expenses 1,346 2,197 4,678 7,750 
EBITDA -9 -104 479 262 
OPM 0% -2% 5% 2% 
Other Income 464 761 1,746 2,526 
Net Profit 371.00 504 1,535 2,106 
NPM 13.11 11.80 14.54 13.11 
EPS 5.54 6.77 22.93 28.29 
Suzlon Energy Ltd
Suzlon Energy Shares Fall 22% in 2025: Opportunity to Buy or Time to Stay Cautious?

Business and Industry Overview: 

Suzlon Energy Ltd is a big company that makes wind turbines, which turn wind into electricity. It was started in 1995 by Tulsi Tanti and is based in Pune, Maharashtra. Suzlon is one of the largest companies in the world that makes wind turbines. It has set up more than 20.9 gigawatts (GW) of wind energy in 17 countries across places like Asia, Europe, and the Americas. Suzlon makes all parts of wind turbines, such as blades, towers, generators, and nacelles (the part that holds the turbine’s inner parts). They do everything, from designing the turbines to making the parts, installing them, and maintaining them. This makes Suzlon a complete service provider for wind energy projects. They offer wind turbines that range from small ones that generate 600 kW of power to larger ones that generate 6.15 MW. The company helps businesses and people who want to use wind energy for their power needs. Suzlon is also working on more projects and has won a big order to set up many wind turbines in Rajasthan. This shows that they are growing and getting more projects. Suzlon’s stock price has been going up, showing that people are interested in the company. Suzlon is trying to reduce its debt by selling some parts of the business that are not important. The company is also getting help from other investors to improve its finances. Overall, Suzlon is helping the world move to clean and renewable energy by producing wind power and growing its business. 

Latest Stock News: 

Shares of Suzlon Energy Ltd moved strongly on Monday, crossing the important Rs 60 level. The stock went up by 9.50% and closed at Rs 60.31. However, it has dropped by 14.59% in the last six months. Recently, Suzlon got a new order for a wind power project of 100.8 MW from Sunsure Energy. The project will be built in Maharashtra’s Jath region. Suzlon will supply 48 wind turbine generators, each producing 2.1 MW of power. Some analysts are positive about the stock for the short term. If the stock moves above Rs 62, it could start a bullish rally. Nilesh Jain, VP at Centrum Broking, said, “We’ve seen a good breakout today. The stock may move towards Rs 62-64. Keep a stop loss at Rs 57.” Kunal Kamble, Senior Technical Research Analyst at Bonanza Group, also said that moving above Rs 62 could show strong buyer interest and lead to more growth. The stock is trading higher than its 5-day, 10-day, 20-day, 30-day, 50-day, and 100-day moving averages but lower than its 150-day and 200-day averages. Its 14-day relative strength index (RSI) is 63.78, which means it is neither overbought nor oversold. According to BSE, Suzlon’s price-to-earnings (P/E) ratio is 172.31, and its price-to-book (P/B) ratio is 21.16. The earnings per share (EPS) is 0.35, and its return on equity (RoE) is 12.36%. Suzlon has a one-year beta of 1.2, meaning the stock is highly volatile. As of March 2025, the promoters of Suzlon own 13.25% of the company. 

Potentials: 

Suzlon Energy Ltd has clear plans for the future to grow in the renewable energy business. First, Suzlon wants to increase the number of wind turbines it installs. They plan to install 4 gigawatts (GW) of wind energy in FY25, 6 GW in FY26, and 8 GW in FY27. This will help Suzlon become a leader in wind energy in the coming years. Second, Suzlon is improving its technology. They are working on better wind turbines and hybrid energy solutions. This will make the turbines more efficient, reliable, and cheaper to use. Suzlon wants to stay competitive and meet the growing demand for renewable energy. Most of Suzlon’s work is in India, and they want to focus on local projects. About 85% of the company’s employees and factories are in India. By working more on projects in India, Suzlon will help the country reach its renewable energy goals. This also matches the Indian government’s plan to make more energy equipment locally and reduce imports. Suzlon is also looking at international markets. They are taking part in global renewable energy events to show their technology and find new business opportunities. This will help them grow and reach more countries. Lastly, Suzlon is committed to helping the environment. They are supporting India’s green hydrogen plan, which aims to produce 5 million tons of green hydrogen per year by 2030. Suzlon also wants to help India reach its goal of having 125 GW of renewable energy by 2030. Suzlon plans to do this by continuing to develop and install wind energy projects. 

Analyst Insights: 

  • Market capitalisation: ₹ 80,255 Cr. 
  • Current Price: ₹ 59.3 
  • 52-Week High/Low: ₹ 86.0 / 37.9 
  • P/E Ratio: 68.6 
  • Dividend Yield: 0.00% 
  • Return on Capital Employed (ROCE): 24.9% 
  • Return on Equity (ROE): 28.8% 

Suzlon Energy is doing well in the renewable energy market. The company has installed over 20 GW of wind energy in 17 countries. This shows their strong presence in the industry. They have grown their profits by 19.7% every year for the past 5 years. In the last year, their profits increased by 136%. This is a good sign for future growth. The company has worked hard to reduce its debt. Now, Suzlon is almost debt-free. This makes the company more financially stable and safer for investors. Their profit margins are strong, ranging from 14% to 18%. This shows they manage costs well while still making a good profit. Suzlon’s stock price is currently at a P/E ratio of 68.6. This is higher than many competitors. However, it is reasonable given the company’s future growth. The stock is also below its book value. This could be an opportunity for investors. Suzlon keeps winning new projects. For example, they recently got a 100.8 MW project from Sunsure Energy. This will bring in more revenue. While Suzlon does not pay dividends, its growth potential makes it attractive for long-term investors. In summary, Suzlon Energy has strong financials, growing profits, and a reduced debt. These are all good signs for investors. The higher stock price and no dividend may be a downside for some. But, for long-term growth, Suzlon looks like a good investment. 

Narayana Hrudayalaya Stock Analysis
Narayana Hrudayalaya Ltd: Healthcare Giant with 47% Stock Growth & ₹37,541 Cr Market Cap

Business and Industry Overview: 

Narayana Health was earlier called Narayana Hrudayalaya. It is a big hospital group in India. It was started in the year 2000. A heart doctor named Dr. Devi Shetty started it. He wanted to help poor people get good treatment. He wanted to make treatment low-cost and easy to get. The first hospital was in Bangalore. It was for heart surgery. Later, more hospitals were opened. Now, Narayana Health has more than 20 hospitals in India. It also has over 5 heart centers. It also has one hospital in the Cayman Islands. That is outside India. Narayana Health is known for heart treatment. It does many heart surgeries every day. Because of this, the cost per surgery becomes less. This helps in giving treatment at a low cost. The hospitals use good machines. They have good doctors too. But the cost is still low. They treat many problems, not just heart. They treat cancer, kidney problems, brain problems, bone problems, children’s health, and more. They help poor people by giving free or low-cost treatment. Some people also get help from insurance or government schemes. Narayana Health also wants to help people in small towns and villages. They use video calls to talk to patients. This is called telemedicine. It helps people get advice from doctors without traveling far. The aim of Narayana Health is to give good treatment to everyone. They want to help all people, rich or poor. Many people in India and other places have got help from their hospitals. 

Latest Stock News: 

On April 22, 2025, Narayana Hrudayalaya’s stock reached a new high of ₹1,872.85. This is the highest the stock has been in the past year. It is a big achievement for the company. However, today the stock is slightly down. It underperformed its sector by 2.19%. This means the stock fell after going up for six days in a row. The lowest the stock price went today was ₹1,813.35, which is a 2.24% decrease. The stock is doing well in the long term. It is above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This shows the stock is on a strong upward trend. Over the past year, Narayana Hrudayalaya’s stock price has gone up by 46.97%. This is much higher than the Sensex, which went up by only 8.18% during the same time. The stock market is also doing well. The Sensex is at 79,054.16 today. Many other market indices, such as S&P BSE Finance and NIFTY BANK, also reached new 52-week highs today. This shows that the overall market is growing, which helps Narayana Hrudayalaya perform better too. In short, Narayana Hrudayalaya’s stock has been doing very well. Even though it dropped a little today, it has grown a lot in the last year. The stock is still in a strong trend, and it is outperforming the market. 

Potentials: 

Narayana Hrudayalaya has big plans for the future. They want to open more hospitals and add more beds. They are planning to build new hospitals in cities like Bengaluru, Kolkata, and Raipur. They also want to expand outside India, like they have already started in the Cayman Islands. The company is using new technology like artificial intelligence (AI) and machine learning to help doctors give better care. This will help doctors make better decisions for each patient. Narayana Hrudayalaya also wants to make it easier for people to get healthcare from home by improving telemedicine services. They have also launched new health plans called Arya Health Plans. These plans will help people get the care they need, including hospital and doctor visits. Narayana Hrudayalaya is also focusing on cancer care. They are investing $10 million to build cancer care centers in cities like Delhi and Mumbai. They want to expand these centers to more cities in the next few years. Overall, Narayana Hrudayalaya is working to grow and improve healthcare services. They want to help more people by opening new hospitals, using technology, and making healthcare easier to access. 

Analyst Insights: 

  • Market capitalisation: ₹ 37,541 Cr. 
  • Current Price: ₹ 1,837 
  • 52-Week High/Low: ₹ 1,873 / 1,080 
  • P/E Ratio: 48.0 
  • Dividend Yield: 0.22% 
  • Return on Capital Employed (ROCE): 26.5% 
  • Return on Equity (ROE): 31.4% 

Narayana Hrudayalaya Ltd. is a strong player in the healthcare sector, showing good performance over the years. The company’s profits have grown at a rate of 67.8% per year for the past five years, showing that its business model is working well. The company is also efficient in using its resources, with a return on equity (ROE) of 31.4% and a return on capital employed (ROCE) of 26.5%. This means that it is making good use of the money it invests and is profitable. 

The company has a solid operating profit margin of 23%, which means it can make consistent profits from its business. This is important in the healthcare sector, where controlling costs and running operations smoothly are key to staying profitable. Narayana Hrudayalaya also has a wide presence, with 40 healthcare facilities in India and the Cayman Islands, which helps spread its risks and create more growth opportunities. 

In terms of valuation, Narayana Hrudayalaya has a market value of ₹37,541 crore and a price-to-earnings (P/E) ratio of 48.0. While this P/E ratio is higher than some other companies, it reflects the confidence investors have in the company’s future growth. The higher P/E ratio is justified by the company’s ability to keep growing and its strong position in the healthcare sector. 

Overall, Narayana Hrudayalaya has strong financials, efficient operations, and a good market position. It is in a growing healthcare sector, with more demand coming from people needing better healthcare. While its valuation is high, the company’s strong growth and solid track record make it a good choice for long-term investment. Therefore, the stock is recommended as a buy. 

Gensol Engineering Ltd
From Clean Energy to Controversy: Gensol Engineering Hit by ED and SEBI Over Fraud Allegations

Business and Industry Overview: 

Gensol Engineering Limited started in 2012. It is the main company of the Gensol Group. It provides engineering, procurement, and construction (EPC) services for solar power projects. The company has a strong team of over 240 professionals. It has completed many projects worldwide. Gensol has installed more than 700 MW of solar power, including both ground-mounted and rooftop projects. Apart from solar, Gensol has entered the electric vehicle (EV) sector. It has built a modern EV manufacturing facility in Pune, India. This facility makes electric three-wheelers and four-wheelers. The EVs have received approval from the Automotive Research Association of India (ARAI). Gensol does not just manufacture EVs but also offers leasing solutions. It provides EV leasing to many clients, including government bodies, multinational corporations, ride-hailing companies, logistics firms, educational institutions, and last-mile delivery services. To strengthen its renewable energy business, Gensol has acquired Scorpius Trackers. This company designs and develops advanced solar tracking systems. These systems improve the efficiency of solar power generation. Gensol is also a major player in the solar operations and maintenance (O&M) sector. It has important clients like Delhi International Airport, Suzlon, Greenko, and Essel Infra. With expertise in both solar and EVs, Gensol is expanding its business and playing a key role in clean energy and electric mobility. 

Latest Stock News: 

Gensol Engineering Limited’s stock hit a 52-week low of ₹110.71 on April 17, 2025, because of serious issues raised by the market regulator, SEBI. On April 15, 2025, SEBI made an interim order after looking into the company’s operations. SEBI found that Gensol’s electric vehicle (EV) plant in Pune had very little activity, with only two to three workers there and no manufacturing happening. This investigation started after a complaint in June 2024, accusing the company and its promoters of manipulating the share price and misusing funds. Gensol had claimed they had pre-orders for 30,000 EVs, but SEBI found these were just MoUs, with no details on pricing or delivery. The company borrowed ₹977.75 crore between FY22 and FY24 for buying EVs, but they only bought 4,704 units, leaving ₹262.13 crore unaccounted for. SEBI also found that money meant for EVs was used for personal expenses, like buying a luxury apartment and transferring money to family members. Because of this, SEBI banned the founders, Anmol and Puneet Singh Jaggi, from holding any important roles or entering the stock market. Since these issues came up, the stock has been falling and hitting lower circuit limits for eight days in a row. 

Potentials: 

Gensol Engineering has a good future because it works in solar power and electric vehicles (EVs), which are growing fast. The company is building more solar projects because many people and businesses want clean energy. It has also bought Scorpius Trackers, a company that makes solar panels work better by following the sun. Gensol also takes care of solar plants to keep them running well for a long time. The company is also making electric three-wheelers and four-wheelers in Pune. Many businesses want EVs because they cost less to run than petrol or diesel vehicles. Gensol helps companies by giving them EVs on rent, so they do not have to spend a lot of money to buy them. Gensol is also working on battery storage and green hydrogen. Battery storage helps save extra solar power for later use. Green hydrogen is a clean fuel that factories may use in the future. These projects will help Gensol grow more. The government is helping solar power and EVs by giving discounts and support. More people and businesses are using solar energy and EVs because they save money and are good for the environment. With new technology, more business, and government help, Gensol can grow a lot in the future. 

Analyst Insights: 

  • Market capitalisation: ₹ 403 Cr. 
  • Current Price: ₹ 106 
  • 52-Week High/Low: ₹ 1,126 / 106 
  • P/E Ratio: 4.67 
  • Dividend Yield: 0.00% 
  • Return on Capital Employed (ROCE): 14.3% 
  • Return on Equity (ROE): 20.1% 

Gensol Engineering Ltd is growing very fast. In the last three years, its revenue grew by 147% every year, and its profit grew by 156% every year. This shows strong business growth. The company works in the solar energy sector, which is growing in India. It also uses its money well. Its return on equity is 20.1%, and return on capital employed is 14.3%. This means the company is earning good profit from the money it uses. The stock is also cheap. The price-to-earnings ratio is 4.67, and the price-to-book ratio is 0.71. These numbers show the stock may be undervalued. 

But there are also big risks. The promoters of the company have pledged 81.7% of their shares. This is very risky. If they cannot repay the loan, it can affect the stock badly. Also, the company has taken a lot of debt. In one year, the debt increased from ₹598 crore to ₹1,372 crore. This is a big jump. The interest coverage ratio is low. It means the company may find it hard to pay interest on its loans. 

The stock price has also fallen a lot. It is 88% down from its 52-week high. This is a big fall. Even though the stock is cheap and the company is growing fast, the high debt and pledged shares are a big problem. 

So, it is better to wait and watch. It is not the right time to buy. Investors should wait until the debt reduces and promoter pledging is lower. 

Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Gains 4% After Cohance Merger Deal and Growth Plans

Business and Industry Overview: 

Suven Pharmaceuticals Ltd is a company based in Hyderabad. It makes medicines and chemicals for other companies. The company started in 2018 after splitting from Suven Life Sciences. It works with clients in countries like North America, Europe, and Asia. Suven Pharmaceuticals is good at making special chemicals and medicines. They focus on making active ingredients and helping other companies create their products. The company can make small to large amounts of products, but it does not do certain processes like fluorination. The company has been growing well. For example, in the third quarter of FY2025, their revenue grew by 39.73% compared to last year. Suven Pharmaceuticals is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). As of April 2025, the stock price is ₹1,168.10. In March 2024, Suven Pharmaceuticals merged with Cohance Lifesciences. This will help the company grow even more and reach more markets. 

Latest Stock News: 

Suven Pharmaceuticals Ltd, as of April 21, 2025, is trading at ₹1,211.25 on the National Stock Exchange (NSE). The stock price has seen a 1.23% increase from its previous close of ₹1,159.25 on March 21, 2025. Over the past month, the stock has experienced a small decline of 1.24%. However, it has shown a positive growth of 2.20% over the last three months. When compared to last year, the stock price has surged significantly by 92.02%, which indicates strong growth and investor confidence in the company. In March 2024, Suven Pharmaceuticals completed a merger with Cohance Lifesciences, which is an important step for the company. The merger is expected to help the company expand its reach and improve its operations. It will also strengthen the company’s position in the pharmaceutical industry, leading to further growth in the future. The positive market reaction to the merger and the stock’s strong performance in the past year suggest that investors are optimistic about Suven Pharmaceuticals’ potential for success in the coming years. 

Potentials: 

Suven Pharmaceuticals is aiming to achieve $1 billion in revenue by 2030. To reach this goal, the company plans to focus on developing new technologies for making medicines. They are working on advanced drug technologies such as flow chemistry, mRNA technology, and peptide synthesis, which are important for creating new types of drugs. These technologies will allow Suven to stay ahead in drug development and offer cutting-edge medicines. In addition to this, Suven is growing by merging with other companies, which helps increase its market presence and revenue. A major merger happened in March 2025 with Cohance Lifesciences, which will help them expand their operations and reach more customers. This merger is a big step in Suven’s plan to grow. Suven is also investing heavily in building new and better factories and research centers. For example, they are building a large 80,000 sq ft facility in the USA. This facility will help them meet the growing demand for their medicines and expand their reach globally. The company is focusing on making specialized drugs and complex formulations. These are the types of medicines that are in high demand and require more advanced techniques to create. This focus will help Suven stay competitive in the global pharmaceutical market. Suven expects its revenue to grow significantly, from ₹2,392 crore in FY24 to ₹6,000 crore by FY29. This shows that the company is planning for steady growth over the next few years, to become a leading player in the global pharmaceutical industry. 

Analyst Insights: 

  • Market capitalisation: ₹ 30,420 Cr. 
  • Current Price: ₹ 1,195 
  • 52-Week High/Low: ₹ 1,360 / 597 
  • P/E Ratio: 109 
  • Dividend Yield: 0.00% 
  • Return on Capital Employed (ROCE): 18.8% 
  • Return on Equity (ROE): 14.1% 

Suven Pharmaceuticals Ltd. has shown good growth. In Q4 FY24, the company’s net profit went up by 77.28%. Its sales grew by 39.73%. These numbers show the company is doing well. The operating profit margin is 38%, which is high and shows good profit from sales. The company has also reduced its debt. It is almost debt-free, which is a good sign for its financial health. However, there are some risks. The P/E ratio is 109. This is much higher than other companies like Dr. Reddy’s Laboratories (P/E 18.41) and Cipla (P/E 24.51). A high P/E ratio can mean that the stock is expensive. It may be overvalued compared to its competitors. Another concern is that promoter holding has dropped by 9.9% over the last 3 years. This could mean that the promoters are not as confident in the company’s future. They might be selling their shares for some reason. The company is strong in the CRAMS sector and continues to grow. But the high P/E ratio and falling promoter confidence are risks to watch. Investors should be careful when buying this stock at its current price. There may be other stocks with lower risk and better value in the market. 

FACT Ltd
Why FACT Ltd is Trending: Surging Volumes, Green Hydrogen Push & Fertilizer Market Moves

Business and Industry Overview: 

Fertilizers and Chemicals Travancore Ltd (FACT) is one of India’s oldest fertilizer companies. It was started in 1943 in Kochi, Kerala. FACT was the first big fertilizer plant in India. The company makes many kinds of fertilizers to help farmers grow crops. It makes Factamfos, which is a complex fertilizer, and Ammonium Sulphate, a straight fertilizer. It also makes organic fertilizers, biofertilizers, and imports Muriate of Potash, which helps improve soil. Besides fertilizers, FACT also makes bagged gypsum, used in construction, and Caprolactam, which is used to make nylon products like tyre cords and nylon yarn for fabrics. FACT has factories that produce these products and supply them across India. This helps farmers grow more food. FACT has a large manufacturing capacity. It can make 2.25 lakh tons of Ammonium Sulphate, 6.34 lakh tons of Factamfos, 50,000 tons of Caprolactam, and 1.73 lakh tons of nitrogen-based fertilizers every year. This makes FACT one of the largest producers in India. The company is also planning to grow. FACT is investing ₹700 crore in new projects. One of these projects is a 1650 TPD NP Plant at its Cochin Division. This will help FACT increase its fertilizer production from 10 lakh tons to 14 lakh tons by 2024-25. This will also help increase its revenue from ₹3,250 crore to ₹5,000 crore in the next few years. FACT is also planning to build a 10,000 MT Ammonia storage tank to support fertilizer production. FACT has a special department called the Engineering and Design Organisation (FEDO). This department helps build factories for ammonia, sulfuric acid, phosphoric acid, hydrogen, and fertilizers.FACT has a lot of debt. Most of it is from loans from the Indian government. The company has asked the government to help reduce the debt. They want the government to forgive the loan interest and convert some of the debt into equity. They also want the remaining debt to be interest-free and repaid over the next 10 years.  

Latest Stock News: 

On April 17, 2025, the share price of Fertilizers and Chemicals Travancore Ltd (FACT) went up a lot. It rose by 13% in one day. The share price reached about ₹758. Many people were buying the stock. More than 1 crore (101 lakh) shares were traded that day. This is 25 times more than the normal number of shares traded in two weeks. This means many investors were interested in FACT on that day. Other fertilizer company stocks also went up. So, the full fertilizer sector did well. People are hopeful about these companies. That may be because of good news, strong business plans, or support from the government. Even though the stock price went up, some experts are cautious. Websites like TradingView gave a “sell” sign. This means the stock may be too expensive now. It may not rise more. It could also fall. The market value of FACT is now over ₹49,000 crore. This is a big amount. FACT gives a small dividend of 0.13%. This means if you hold the stock, you get a small return from the company. Also, the price-to-earnings (PE) ratio is high. This shows the stock price is high compared to the company’s earnings. In short, the stock price of FACT went up a lot. Many people bought it. But the stock may be expensive now. So it is good to be careful and watch the stock closely. 

Potentials: 

Fertilizers and Chemicals Travancore Ltd (FACT) has many plans. The company wants to make more fertilizers. Right now, it makes 10 lakh metric tons every year. FACT wants to increase this to 15 lakh metric tons. For this, it will spend over ₹1,000 crore. This money will be used to buy new machines and fix old machines. This will help the company make more fertilizers and earn more money. FACT also wants to use clean energy. It is working with Oil India Limited to make a small green hydrogen plant in Kochi. Green hydrogen is a clean fuel. It is made using sunlight or wind. This fuel does not cause pollution. This will help FACT protect the environment. FACT is also planning to make electricity using sunlight. It wants to build a solar power plant at Ambalamedu. The plant will be built on top of a water area. This will give clean energy and reduce the use of dirty fuels. FACT has made a new type of liquid fertilizer. It is called Magnesium Fortified Calcium Nitrate. It helps plants take in nutrients better. It helps plants grow faster and healthier. The government has approved this fertilizer. FACT has also improved one of its plants in Udyogamandal. It changed some things in the factory to make more Ammonium Sulphate. Now the plant makes 100 tons more every day. These changes were made by FACT’s team. All these plans will help FACT grow. It will make more fertilizers. It will use clean energy. It will help farmers. It will also protect nature. 

Analyst Insights: 

  • Market capitalisation: ₹ 49,232 Cr. 
  • Current Price: ₹ 761 
  • 52-Week High/Low: ₹ 1,187 / 565 
  • P/E Ratio: 589 
  • Dividend Yield: 0.13%
  • Return on Capital Employed (ROCE): 16.9% 
  • Return on Equity (ROE): 29.4% 

FACT (Fertilizers and Chemicals Travancore Ltd) is facing many problems in its business and finances. In Q3 FY25, the company’s profit fell by 73.6%. It made only ₹8 crore profit, compared to ₹30 crore last year. Its revenue also went down by 13.5% to ₹949 crore. This means the company is selling less or facing higher costs. In the past 12 months, the company had a total loss of ₹91 crore. Its operating profit margin is also low at 3.32%, which shows the company is not controlling its costs well. The stock is very expensive. Its price-to-earnings (P/E) ratio is 589, and its price-to-book (P/B) ratio is 38. These numbers are very high and do not match the company’s weak results. Other companies in the same sector, like Coromandel International and Chambal Fertilizers, are doing better. They have higher profits and better margins. FACT also has a low interest coverage ratio. This means it may have trouble paying interest on its loans. The company had good performance in the past. Its 3-year return on equity (ROE) is 56.4%. But this is from earlier years. Now, its performance is getting worse. The company is in an important sector, but unless it improves its profits and sales, the stock may not do well in the future. 

Zydus Lifesciences Ltd
Zydus Lifesciences Patent Challenge in US Over Myrbetriq and Stock Insights

Business and Industry Overview: 

Zydus Lifesciences Limited, formerly called Cadila Healthcare Limited, is a top Indian pharmaceutical company. It is a global healthcare provider with expertise in healthcare. Zydus works across the full pharmaceutical value chain. This includes making medicines, active ingredients, animal healthcare products, and wellness products. The company is known in India for offering complete healthcare solutions. Zydus has a rich history. It was founded in 1952 by Mr. Ramanbhai B. Patel (late), who was a first-generation entrepreneur and a leader in the Indian pharmaceutical industry. The company started in the 1950s. In 1995, the company changed its structure and formed Cadila Healthcare under the Zydus group. It grew from a turnover of ₹250 crores in 1995 to more than ₹19,500 crores in FY-24. Zydus is dedicated to improving life in all ways. The company continues to innovate and focus on solving healthcare problems that are not yet addressed. It also works to make communities around the world healthier and happier. 

Latest Stock News: 

As of April 17, 2025, Zydus Lifesciences Limited’s stock is trading at ₹825.40 on the BSE and ₹998.90 on the NSE. The stock’s price today has been between ₹816.10 and ₹839.15. Over the past 52 weeks, the highest price was ₹1,324.30, and the lowest was ₹795.00. Zydus Lifesciences has a market value of ₹83,055 crore. This is the total value of the company based on its stock price. The company pays a dividend of 0.36%, which means investors get 0.36% of the stock price as dividends. The stock has a Price-to-Earnings (P/E) ratio of 18.95, which helps to understand if the stock price is too high or too low compared to the company’s earnings. Analysts have different opinions about the stock. Three analysts say “strong buy,” nine say “buy,” ten say “hold,” three say “sell,” and two say “strong sell.” This shows that some analysts believe the stock will do well, while others expect it to decline. For the fiscal year 2024, Zydus Lifesciences made a net profit of ₹3,859.50 crore. This is the amount left after all expenses are paid. However, the stock has gone down in recent months. In the past three months, it has fallen by 16.93%. In the past six months, it has dropped by 19.06%. At 14:47 IST on April 17, 2025, Zydus Lifesciences’ stock fell by 7.65% to ₹816.55. It became the biggest loser in the BSE’s ‘A’ group, which has high-value stocks. So far, 2.23 lakh shares were traded on the BSE, much higher than the usual 74,937 shares traded daily over the last month. This shows that more people are trading the stock, likely because of the price drop. 

Potentials: 

Zydus Lifesciences has many future plans. The company wants to grow in the US market. It plans to launch a new liver medicine called Saroglitazar in the US by early 2026. This medicine helps in liver problems like Primary Biliary Cholangitis (PBC) and MASH. Zydus is also working on special medicines for rare diseases and complex injectables (injection-based medicines). These are harder to make and are used in serious health problems. To grow faster, Zydus wants to join with other companies, buy small companies, or get rights to sell special medicines. This will help the company grow its US business in generic drugs and injections. Zydus is also working on new medicines. It is focusing on making new chemical medicines for problems like heart diseases, inflammation, and fibrosis. The company is also building a group of complex medicines. These include injectables, skin patches (transdermals), and biosimilars. Biosimilars are cheaper copies of expensive modern medicines. Zydus also wants to work more in the rare disease area. It has already bought a medicine for Menkes disease, a rare illness. Zydus is entering new business areas too. It now wants to make products in medical devices, health tests (diagnostics), and nutrition. For this, it bought Naturell India Pvt. Ltd., the company that makes Ritebite Max Protein bars. This helps Zydus enter the protein and nutrition market. The company is also working with other groups. It has a joint venture with Perfect Day Inc. to make animal-free protein products. It has a partnership with CVS Caremark to sell medicines in the US. Zydus is also working with the Gates Foundation to make a new vaccine. This vaccine will fight shigellosis and typhoid. Another new medicine by Zydus is ANVIMO. It helps organ transplant patients. This medicine is made in India and will be affordable and easy to get. Zydus wants to give better and cheaper healthcare to more people. It plans to make modern, useful, and safe medicines for people in India and the world. 

Analyst Insights: 

  • Market capitalisation: ₹ 83,236 Cr. 
  • Current Price: ₹ 827 
  • 52-Week High/Low: ₹ 1,324 / 795 
  • Stock P/E: 18.4 
  • Dividend Yield: 22.3 % 
  • Return on Capital Employed (ROCE): 22.3 % 
  • Return on Equity: 20.7 % 

Zydus Lifesciences Ltd is showing strong growth. Its Q4 FY25 results were very good. Net profit grew by 33.34%. It reached ₹1,026 crore. Last year, it was ₹769 crore. Revenue also increased by 16.96%. It became ₹5,832 crore in Q4 FY25. This means the company is selling more. The profit margin also improved. EBITDA margin is now 26%. It was 23.2% last year. This shows the company is managing costs well. For the full year FY25, net profit was ₹4,675 crore. In FY23, it was ₹3,164 crore. This shows the company is growing every year. Zydus also reduced its debt. In FY23, total debt was ₹1,195 crore. Now, in FY25, it is only ₹190 crore. This is a big improvement. The company is almost debt-free. This helps in saving interest costs. Its Return on Capital Employed (ROCE) is 22.34%. This means Zydus is using its money well. It is earning a good profit from the money it uses. The Price-to-Earnings (P/E) ratio is 18.4. This is low compared to other pharma companies. It means the stock is not too expensive. The company’s Earnings Per Share (EPS) is also growing. Profit margins are improving. The company is working well in India and outside India. It also launched new products in the U.S. market. Zydus has a strong base. It is growing, reducing debt, and increasing profit. It is a stable and healthy company. These are good signs for investors. 

Sai Life Sciences Ltd
Sai Life Sciences: From Hyderabad to the World – Pharma Success Story

Business and Industry Overview: 

Sai Life Sciences helps pharma and biotech companies make new medicines faster. It started 25 years ago and is based in Hyderabad, India. It also has offices in the USA, UK, and Japan. The company works on drug research, testing, and making medicines in large amounts. It is growing fast and is one of the fastest-growing companies in its field in India. It has worked with over 280 companies around the world to develop new medicines. It has a team of 2,845 people working in different locations. The company makes high-quality medicines at a good cost and delivers them on time. It also makes important drug ingredients for markets in the USA, Europe, and Japan. Its factories are built to handle complex drug-making and follow strict safety and quality rules. It keeps improving its research and factories to serve more customers. It aims to help bring 25 new medicines to market by 2025. It is investing in better technology and processes to reach this goal. 

Sai Life Sciences is one of the fastest-growing companies in its field in India. It is growing faster than the industry with an expected growth rate of 15-20% per year. The company has a strong market position and serves over 280 global pharma and biotech companies, including 18 of the top 25 biggest pharma firms. It operates in highly regulated markets like the US, UK, and Europe, which gives it a strong international presence. Sai Life Sciences is benefiting from global supply chain shifts, making it an important player in the industry. 

Latest Stock News: 

On April 16, 2025, Sai Life Sciences Ltd had a strong day in the stock market. By 14:14 IST, the company saw a huge jump in its stock trading. A total of 48.83 lakh shares were traded. This is 12.31 times more than the usual trading volume of 3.97 lakh shares over the last two weeks. The stock price increased by 13.38%, reaching ₹759.05. This is a significant gain for the company. In the previous session, the volume was much lower, with only 1.87 lakh shares being traded. The surge in trading could be because of some recent positive news. Sai Life Sciences recently opened a new Peptide Research Center in Hyderabad. This could be seen as a step forward for the company in research and development. This might have increased investor confidence. The company also reported impressive financial results. In FY24, the company saw a massive 729% growth in its profits. This positive financial performance has made the company more attractive to investors. Sai Life Sciences also had a very successful IPO in December 2024. The IPO was subscribed 10.27 times. This means a lot of people were interested in buying the shares, which shows strong market demand. 

Potentials: 

Sai Life Sciences, a leading company in research, development, and manufacturing for medicines, has big potential in the global pharmaceutical and biotech industry. It is growing fast because of its strong science, wide global reach, and focus on new ideas and sustainability. The global medicine-making industry is growing as big companies look for new partners outside China, and Sai Life Sciences is in a great position to benefit from this trend. It is the fastest-growing company in its field in India in terms of revenue and profit growth over the last three years. The company works in major global markets like India, the UK, the USA, and Japan, helping over 280 pharmaceutical and biotech companies make and develop new medicines. It has research centers in Boston, Hyderabad, and the UK. Sai Life Sciences focuses on new scientific ideas, better technology, and advanced medicine-making methods. It has expert scientists and custom labs to create better drugs and solutions. The company is also working to reduce pollution by cutting down harmful gas emissions and using cleaner technology. It is investing in better facilities, digital tools, and research to stay ahead. Sai Life Sciences has repaid most of its loans, which will help it save money and grow faster. It plans to keep expanding, improve its services, and bring in more customers while helping big pharma companies find reliable partners. With strong orders, new projects, and better operations, the company is set to grow even more in the future. 

Analyst Insights: 

  • Market capitalisation: ₹ 15,429 Cr. 
  • Current Price: ₹ 740 
  • 52-Week High/Low: ₹ 809 / 635 
  • P/E Ratio: 186 
  • Dividend Yield: 0.00% 
  • Return on Capital Employed (ROCE): 10.6% 
  • Return on Equity (ROE): 8.89% 

Sai Life Sciences Ltd. is a good company to buy. It has grown a lot in the last year. Its profits have increased by 711%. This shows it is becoming much more profitable. The company’s sales have gone up by 24% in the last 3 years. This means it is making more money from its products. The company does a lot of work in research and development (R&D). It has completed 200+ programs to discover new medicines. 40+ of these programs have moved to clinical trials, which is a big step in creating new drugs. Sai Life Sciences is good at drug chemistry, metabolism, biology, and other important areas for making medicines. The company is also improving its business. For example, debtor days (the time it takes to get paid) have dropped from 83.6 days to 63.8 days. This means the company is collecting money faster. Also, working capital days (the time it takes to use money for daily needs) have gone down from 180 days to 130 days. This means the company is managing its money better. Sai Life Sciences works with 17 of the top 20 global pharmaceutical companies. It focuses on areas like cancer, brain disorders, inflammation, and antiviral treatments. These are important areas that are growing, which means the company can keep growing in the future. But, there are some things to think about. The company’s P/E ratio (which shows how expensive the stock is compared to its profit) is 186. This is high, meaning the stock might be expensive for some investors. Also, the company doesn’t give dividends, so if you want regular payments from your investment, this might not be a good choice for you. But, this also means the company is using its money to grow more, which can be good for people who want to invest for the long term. In short, Sai Life Sciences is a strong company that is growing. It has good prospects and works with big pharmaceutical companies. Even though the stock is expensive and doesn’t give dividends, it can still be a good choice for long-term investment. 

GM Breweries Ltd
GM Breweries Ltd: IMFL Growth, Dividend Payouts & Q4 Results Breakdown

Business and Industry Overview: 

GM Breweries Ltd was started in 1981 by Shri Jimmy William Almeida. It is a company based in Mumbai, Maharashtra. The company makes two main types of liquor: Country Liquor (CL) and Indian Made Foreign Liquor (IMFL). Some of its well-known brands are G.M. Santra, G.M. Doctor, G.M. Limbu Punch, and G.M. Dilbahar Sounf. 

The company has a big factory in Virar, Maharashtra, which is fully automated. This means the factory runs with little human help. It can produce more than 50,000 cases of drinks every day. This makes GM Breweries one of the biggest makers of country liquor in Maharashtra. 

GM Breweries has been paying dividends to its investors regularly. This means the company gives a part of its profits to the people who own its stock. The company has been doing this since it first became public. 

As of April 2025, the stock price of GM Breweries is around ₹654. The company’s market value (market cap) is about ₹1,494 crore. The P/E ratio (Price-to-Earnings) is 9.63, which is low. This suggests that the stock may be priced lower than its earnings, making it a good investment for people looking for value. 

In short, GM Breweries is a strong company in the alcoholic drinks business. It has a large factory, popular brands, and a good history of paying dividends. Its stock is priced lower than some others, which might be a good chance for investors. 

Latest Stock News: 

GM Breweries Ltd recently shared its Q4 FY25 results. The company reported a 30% drop in net profit, which was ₹60 crore. Even though profit went down, the company’s revenue went up by 6%, reaching ₹663 crore. The company’s earnings per share (EPS) dropped to ₹26.47, which is almost half of what it was last year. The reason for the profit drop was an increase in expenses, which went up by 6%, reaching ₹635 crore. 

Despite the profit decline, GM Breweries decided to give a dividend of ₹7.5 per share to its investors for the year ending March 31, 2025. This shows that the company is still focused on rewarding its shareholders. 

As of April 15, 2025, the stock price of GM Breweries is around ₹654. The company’s market value is about ₹1,494 crore. The P/E ratio (Price-to-Earnings) is 9.63, which is low and might be a good sign for investors looking for value. 

Business Segmental Information of GM Breweries Ltd 

GM Breweries Ltd works in two main areas: 

  1. Country Liquor (CL): 
     
  • Country liquor is one of the main drinks that GM Breweries makes and sells. It is a traditional drink enjoyed by many people, especially in Maharashtra. 
  • GM Breweries is the largest maker of country liquor in Maharashtra and has a big share in the market for this product.
  • Some of the popular country liquor brands from GM Breweries are G.M. Santra, G.M. Doctor, G.M. Limbu Punch, and G.M. Dilbahar Sounf. These drinks are sold at low prices to reach many customers. 
  1. Indian Made Foreign Liquor (IMFL): 
  • IMFL is another key area for GM Breweries. IMFL includes drinks like whiskey, rum, gin, and vodka, made in India using foreign methods. 
  • GM Breweries makes and sells different IMFL brands, catering to customers who want higher-quality alcoholic drinks. 
     

Both of these segments help GM Breweries earn revenue. The company has a large, fully automatic bottling plant in Virar, Maharashtra. This plant helps the company make many bottles of alcoholic drinks quickly and efficiently. The company also pays a lot in excise duty and value-added tax from selling these drinks. 

In short, GM Breweries is a major player in both the country liquor and IMFL markets. It has a strong presence in Maharashtra and other states, offering drinks that cater to different tastes. 

Subsidiary Information of GM Breweries Ltd 

Right now, GM Breweries Ltd does not have any subsidiary companies. This means the company does not own other businesses. It mainly works on its own, making and selling alcoholic drinks like Country Liquor and Indian Made Foreign Liquor (IMFL). 

GM Breweries has its own bottling plant in Virar, Maharashtra, where it makes its drinks. The company focuses on growing its business in these areas. 

In the future, GM Breweries may decide to start new businesses or partnerships, but at the moment, it only operates its main business. 

Q4 Highlights of GM Breweries Ltd (FY25) 

Here are the main points from GM Breweries’ Q4 FY25 results: 

  1. The company’s net profit went down by 30% compared to last year. It was ₹60 crore for this quarter. 
  1. GM Breweries made 6% more money from sales, which added up to ₹663 crore.  
  1. The Earnings Per Share (EPS) dropped to ₹26.47. This is about half of last year’s EPS.  
  1. The company’s total expenses increased by 6%, reaching ₹635 crore. This affected the company’s profit. 
     
  2. Even though profits went down, GM Breweries decided to give a dividend of ₹7.5 per share for the year ending March 31, 2025. 

    Financial Summary:  

    Amount in ₹ Crore Q4 FY24 Q4 FY25 FY23 FY24 
    Revenue 160.00 169.00 615 637 
    Expenses 135.00 141 508 519 
    EBITDA 25 29 107.00 118.00 
    OPM 16% 17% 17% 18% 
    Other Income 71 40 80 48 
    Net Profit 87.00 60.00 152 129 
    NPM 54.38 35.50 66.46 56.48 
    EPS 38 26.46 126.88 134.2 
    Apollo Hospitals ltd
    Apollo Hospitals Strong Financial Growth: A Look at India’s Leading Healthcare Provider

    Business and Industry Overview: 

    Apollo Hospitals started in 1983 in Chennai, India, by Dr. Prathap C. Reddy. It was the first private hospital of its kind in India. It changed healthcare in India by offering better care and treatments. Today, Apollo has 71 hospitals in India. It is the biggest private hospital chain in the country. These hospitals are in big cities like Chennai, Hyderabad, Bengaluru, Kolkata, Delhi, and Ahmedabad. Apollo offers care for many problems like heart disease, bone problems, brain issues, and cancer. Apollo is known for treating serious health problems. They use the latest technology and have doctors from all over the world. Many people trust Apollo for good care. Apollo is growing. They plan to add over 2,000 more beds in their hospitals by 2027. This will help more people get care. Apollo also helps train doctors, nurses, and healthcare workers. They also do research to find better treatments. In 2024, Apollo made 63% more money than the previous year. This is because more people are using their services. Apollo’s goal is to give the best care, keep patients safe, and use technology to improve health. They want to make healthcare affordable for everyone in India and other countries. 

    Latest Stock News: 

    Apollo Hospitals’ stock dropped by 6.7% on April 11, 2025, because the overall stock market went down. This drop was not due to problems with Apollo itself. Despite this, Apollo is still one of the biggest and most important healthcare companies in India. Apollo is planning to grow a lot in the next few years. They are going to invest ₹6,000 crore to add 3,500 new hospital beds over the next five years. This will help Apollo meet the growing demand for healthcare. In the first phase, they will spend ₹2,880 crore to add 1,737 beds in big cities like Pune, Kolkata, Hyderabad, and Gurgaon. They plan to complete this by 2026. In the second phase, Apollo will add 1,775 more beds in cities like Chennai, Mumbai, Varanasi, and Lucknow. This will help more people in both big and small cities get better healthcare. Apollo’s plan to add more beds shows that the company is working to make healthcare easier for more people in India. Even though their stock went down recently, Apollo’s growth plans show they have a strong future. 

    Potentials: 

    Apollo Hospitals has big plans for the future. They want to spend ₹6,100 crore to grow and help more people. They plan to add 3,500 new beds in 11 places across India by 2026. This will allow Apollo to treat more patients and give them better care. Apollo will open five new hospitals in big cities like Mumbai, Chennai, Gurgaon, Varanasi, and Lucknow. These hospitals will have over 1,400 beds. They will also make their current hospitals bigger in cities like Pune, Kolkata, and Hyderabad. This will provide more space for patients and doctors. Apollo will spend ₹1,700 crore for this expansion. Out of this, ₹1,300 crore will be spent in the next year. This shows that Apollo is serious about improving healthcare in India. 

    Apollo is also improving their online services. They want to make it easier for people to talk to doctors. Through telemedicine and online consultations, people can talk to doctors from home. This will help people who cannot visit a hospital easily. These plans will help Apollo provide better healthcare. It will also help treat more people across India. Apollo is working hard to make healthcare available for everyone. 

    Analyst Insights: 

    • Market capitalisation: ₹ 99,147 Cr. 
    • Current Price: ₹ 6,896 
    • 52-Week High/Low: ₹ 7,545 / 5,691 
    • Stock P/E: 75.6 
    • Dividend Yield: 0.24% 
    • Return on Capital Employed (ROCE): 15.1% 
    • Return on Equity: 13.3% 

    Apollo Hospitals is a strong company with solid financial growth. Over the last five years, its profits have grown by 34.3% each year on average. This shows it can keep growing in the future. The company has been able to increase both its revenue and profit margins, even during difficult times. In Q4 FY24, Apollo Hospitals reported a 51.77% increase in net profit, reaching ₹379 crore. This is a big jump and shows the company is still doing well despite challenges. The operating profit margin is 14%, which means Apollo is good at controlling its costs. Apollo’s return on capital employed (ROCE) is 15.1%, which shows it uses its money effectively to make more profit. Its return on equity (ROE) is 13.3%, which means it uses shareholders’ money well to earn profits. The company has a large network of 10,134 beds across India and abroad. This helps it cover a large part of the healthcare market. It also helps the company make more revenue. The healthcare industry is growing, and Apollo is in a good position to take advantage of this. 

    Apollo Hospitals also pays a dividend of 22.6%. This is attractive for investors who want regular income. So, Apollo is a good choice for investors looking for both growth and income. 

    The company’s price-to-earnings (P/E) ratio is 75.6, which is higher than many other companies. This shows that investors expect Apollo to keep growing. Even with the high P/E ratio, it makes sense because Apollo is a leader in the healthcare field. Its high-margin services, like specialized care and retail drugs, are doing well. 

    Overall, Apollo Hospitals is a strong choice for investors. It has shown good financial growth, is well-managed, and is a leader in the healthcare market. Investors looking for long-term growth in healthcare should consider Apollo Hospitals.